Jefferies resumed coverage on Cellectis with a new price target
$CLLS
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2026 | $9.00 | Overweight | Barclays |
| 2/17/2026 | $7.00 | Buy | Jefferies |
| 3/17/2023 | $6.00 | Buy | Bryan Garnier |
| 5/18/2022 | $10.00 | Neutral → Outperform | Robert W. Baird |
| 1/6/2022 | $16.00 | Overweight → Equal-Weight | Wells Fargo |
| 11/30/2021 | $20.00 | Mkt Outperform | JMP Securities |
| 11/8/2021 | Outperform → Mkt Perform | William Blair | |
| 10/8/2021 | $39.00 → $10.00 | Outperform → Neutral | Baird |
6-K/A - Cellectis S.A. (0001627281) (Filer)
6-K - Cellectis S.A. (0001627281) (Filer)
6-K - Cellectis S.A. (0001627281) (Filer)
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer. The appointments deepen the company’s leadership bench as Prolynx advances multiple ultra-long-acting candidates for obesity and related metabolic diseases toward IND-enabling studies. "We believe long-acting agents with the potential to be dosed on a monthly or quarterly basis represent one of the most important next frontiers for the l
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 55,84% of voting rights were exercised, resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors. The detailed results of the vote and the resolutions are available on Cellectis’ website:https://www.cellectis.com/en/investors/g
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. BALLI-01 clinical trial evaluating la
Barclays initiated coverage of Cellectis with a rating of Overweight and set a new price target of $9.00
Jefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00
Bryan Garnier initiated coverage of Cellectis with a rating of Buy and set a new price target of $6.00
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 dataset expected in Q4 2026 Innovation Preclinical data on TALE-based epigenetic editing, a non-DNA cutting approach, to be presented at ASGCT Servier (through Allogene): Interim pivotal data reported from the ALPHA3 trial of cema-cel (n=24) 58.3% of patients in the cema-cel arm achieved MRD negativity versus 16.7% in the observation armFavorable safety profile: no cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse EventsStudy accrual expected to be comple
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2026 ending March 31, 2026 on Monday, May 11, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com About Cellectis Cellectis
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2025 results and an update on business activities. Details for the call are
SC 13D/A - Cellectis S.A. (0001627281) (Subject)
SC 13G/A - Cellectis S.A. (0001627281) (Subject)
SC 13G/A - Cellectis S.A. (0001627281) (Subject)
EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said
UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, 20241; cash runway projection into 2027Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation